Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer

MONDAY, April 22, 2024 -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).The...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news